Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome.

Autor: Algera JP; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Electronic address: joost.algera@gu.se., Törnblom H; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Simrén M; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Center for Functional GI & Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jazyk: angličtina
Zdroj: Current opinion in pharmacology [Curr Opin Pharmacol] 2022 Oct; Vol. 66, pp. 102284. Date of Electronic Publication: 2022 Sep 05.
DOI: 10.1016/j.coph.2022.102284
Abstrakt: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction affecting 4% of the world's population. Patients with IBS experience chronic or recurrent abdominal pain in combination with altered bowel habits (diarrhea and/or constipation), and have reduced quality of life. Despite the high prevalence and substantial burden of IBS, its pathophysiology is incompletely understood and remains to be elucidated. The importance of the gut microenvironment has been highlighted in IBS, as there are signs that the gut microbiota of patients differs from healthy controls. Recent studies have aimed to alter the gut microbiota and thereby, attempted to alleviate gastrointestinal symptoms in IBS patients. We highlighted recent advances in common treatments that are targeting the luminal gut microbiota in IBS.
Competing Interests: Conflict of interest statement JA declares no conflicts of interest. HT has served as consultant and/or speaker for Biocodex, Tillotts, Takeda and Falk foundation. MS has received unrestricted research grants from Glycom and Danone Nutricia Research, and served as advisory board member/consultant and/or speaker for Biocodex Glycom, Danone Nutricia Research, Ironwood, Genetic Analysis AS, Kyowa Kirin, Menarini, Arena, Adnovate, Tillotts, Takeda, Alimentary Health, AlfaSigma, Falk Foundation and Shire.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: